The information contained in these releases was current on the date the releases were issued and will become outdated over time. Lilly does not assume any responsibility for updating information in these releases.
Releases
 |
Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
Feb 3, 2010
|
12.3 KB |
|
| |
INDIANAPOLIS, Feb 03, 2010 /PRNewswire via COMTEX News Network/ -- In a new study, 60 mg of Cymbalta(R) (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.(1) The data were presented today at the annual meeting of the American Acade...
|
|
New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Jan 5, 2010
|
15.4 KB |
|
| |
PARSIPPANY, N.J. and INDIANAPOLIS, Jan 05, 2010 /PRNewswire-FirstCall via COMTEX News Network/ -- Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient((R)) (prasugre...
|
|
Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
Dec 15, 2009
|
14.9 KB |
|
| |
SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy...
|
|
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Dec 14, 2009
|
16.4 KB |
|
| |
INDIANAPOLIS, Dec 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today. ZYPREXA RELPREVV, a long-acting intramuscular inje...
|
|
Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign
Dec 11, 2009
|
11.9 KB |
|
| |
CHICAGO, Dec 11, 2009 /PRNewswire-USNewswire via COMTEX News Network/ -- Chicago Bears' quarterback Jay Cutler and Eli Lilly and Company (Lilly) have already helped send 44 children to American Diabetes Association diabetes camps next summer - with four games left in the NFL season.
Through the Touchdowns for Diabetes campaign, Lilly donates money...
|
|
Lilly Announces the First 300-unit Vial of Insulin
Dec 7, 2009
|
11.5 KB |
|
| |
INDIANAPOLIS, Dec 07, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced the availability of a smaller insulin vial, the first in the United States containing 3 mL (300 units) of insulin, for people with diabetes being treated in a hospital.
The new smaller vial - for Lilly's Humalog(R) (insuli...
|
|
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Dec 4, 2009
|
15.4 KB |
|
| |
INDIANAPOLIS, Dec 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- The U.S. Food and Drug Administration (FDA) today approved Zyprexa(R) (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.
The updated Zyprexa label ...
|
|
New Web Site Fills in the Missing Pieces That May Be Hindering Recovery From Depression
Nov 30, 2009
|
8.7 KB |
|
| |
INDIANAPOLIS, IN, Nov 30, 2009 (MARKETWIRE via COMTEX News Network) -- People living with depression have a new resource to help them get well and take back their lives. A group of leading mental health experts, in partnership with Eli Lilly and Company, has launched a new program, called Missing Pieces, and corresponding Web site (www.MissingPiece...
|
|
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
Nov 30, 2009
|
12.5 KB |
|
| |
INDIANAPOLIS, Nov 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE: LLY) announced today.
"Since generalized anxiety disorder can be a chronic ill...
|
|
New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
Nov 18, 2009
|
11.2 KB |
|
| |
PARSIPPANY, N.J. and INDIANAPOLIS, Nov 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Effient(R) (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardi...
|
|
Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Nov 15, 2009
|
12.6 KB |
|
| |
ORLANDO, Florida, Nov 15, 2009 (PR Newswire Europe via COMTEX News Network) -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Efient(R) (prasugrel) achieved significantly greater platelet inhibition compared with a 600 ...
|
|
Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Nov 15, 2009
|
14.6 KB |
|
| |
ORLANDO, Fla., Nov 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Effient(R) (prasugrel) achieved significantly greater platelet inhibition compared with a 600 ...
|
|
Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
Nov 2, 2009
|
15.0 KB |
|
| |
SAN DIEGO and INDIANAPOLIS, Nov 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following statement in response to the U.S. Food and Drug Administration (FDA) update on BYETTA(R) (exenatide) injection.
"The FDA update issued today aligns ...
|
|
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Oct 30, 2009
|
15.8 KB |
|
| |
SAN DIEGO and INDIANAPOLIS, Oct 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA(R) (exenatide) injection. BYETTA is now approved for use as a st...
|
|
Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
Sep 24, 2009
|
15.3 KB |
|
| |
SAN DIEGO, Calif., INDIANAPOLIS, Ind., and CAMBRIDGE, Mass., Sept 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study ...
|
|
Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer
Sep 21, 2009
|
15.5 KB |
|
| |
INDIANAPOLIS, Sept 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Data published today in The Lancet showed a survival benefit in nonsquamous patients with advanced non-small cell lung cancer (NSCLC) who received maintenance therapy with ALIMTA(R) (pemetrexed for injection) plus best supportive care as compared to placebo plus best supp...
|
|
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta®
Sep 11, 2009
|
14.8 KB |
|
| |
INDIANAPOLIS, Sept 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- In the news release, New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R), issued 11-Sep-2009 by Eli Lilly and Company over PR Newswire, the third paragraph, third sentence should read "A total of 18 patients in the study discontinued...
|
|
Know Fibro Initiative Commemorates National Pain Awareness Month
Sep 8, 2009
|
10.0 KB |
|
| |
INDIANAPOLIS, Sept 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- For people living with painful conditions, September is a time for their true stories of triumph to emerge. Helping to foster support and communication, National Pain Awareness Month allows people with painful conditions to educate others about their experiences, build co...
|
| Showing 1-18 of 18 |
Page: 1 |
|
|
